CK-4015089 is under clinical development by Cytokinetics and currently in Phase I for Muscular Dystrophy. According to GlobalData, Phase I drugs for Muscular Dystrophy does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the CK-4015089 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CK-4015089 overview
CK-4015089 (CK-089) is under development for the treatment of muscular dystrophy and other conditions of impaired muscle function. It is administered through oral route and acts by targeting fast skeletal muscle troponin activator (FSTA).
Cytokinetics overview
Cytokinetics is a biopharmaceutical company with a focus on the discovery, development, and commercialization of muscle activators and muscle inhibitors as potential treatments for debilitating diseases wherein muscle performance is affected. The company develops small molecule drug candidates which is designed to affect muscle function and contractility. Cytokinetics is developing aficamten, a next-generation cardiac myosin inhibitor, to treat hypertrophic cardiomyopathy (HCM). It is also developing Muscle biology-directed research, neuromuscular, cardiac myosin activator and additional skeletal muscle activators. Cytokinetics is headquartered in South San Francisco, California, the US.
For a complete picture of CK-4015089’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.